SASH1 (SAM and SH3 domain-containing protein 1) is a tumor suppressor protein that has roles in key cellular processes including apoptosis and cellular proliferation. As these cellular processes are frequently disrupted in human tumours and little is known about the role of SASH1 in the pathogenesis of the disease, we analysed the prognostic value of SASH1 in non-small cell lung cancers using publicly available datasets. Here, we show that low SASH1 mRNA expression is associated with poor survival in adenocarcinoma. Supporting this, modulation of SASH1 levels in a panel of lung cancer cell lines mediated changes in cellular proliferation and sensitivity to cisplatin. The treatment of lung cancer cells with chloropyramine, a compound that increases SASH1 protein concentrations, reduced cellular proliferation and increased sensitivity to cisplatin in a SASH1-dependent manner. In summary, compounds that increase SASH1 protein levels could represent a novel approach to treat NSCLC and warrant further study.
Lung cancer is the most commonly diagnosed cancer in the world (excluding non-melanoma skin cancers) and the fifth most common in Australia, where it is responsible for almost one in five cancer deaths1. The five-year patient survival rate of lung cancer is ~ 15%. Clearly, there is an unmet need for new therapeutic interventions, to improve the overall response rate and subsequent survival rate of lung cancer patients.
SAM and SH3 domain containing 1 (SASH1) was initially identified as a putative tumor suppressor gene, based on detection of significantly lower mRNA levels in lung, breast, thyroid and colorectal cancers compared to adjacent normal tissue2,3. SASH1 has previously been recognized as having a potential role in lung cancer susceptibility with the SASH1 gene located at a major lung cancer susceptibility locus on Chromosome 6q23-254,5. Low mRNA expression of SASH1 correlates with poor prognosis in colon cancer6 and glioma7. In support of its role as a tumour suppressor, several recent studies have demonstrated that SASH1 opposes cancer cell proliferation, mesenchymal differentiation, migration and invasive cell behaviour in hepatocarcinoma, thyroid and cervical cancer cell lines3,7,8,9,10,11,12. Recent studies suggest that promoter hypermethylation correlates with SASH1 repression in tumours13,14. SASH1 localises to the nucleus, and its SAM and SH3 domains imply signalling, adaptor and/or molecular scaffold functions, although the precise molecular functions of SASH1 in normal tissues and cancer remain to be fully elucidated15,16. SASH1 can regulate signalling through focal adhesion kinase (FAK) and AKT/PI3K3,10 and promote apoptosis3,8. SASH1 has also been shown to be required for embryonic development by the regulation of alveolar epithelium cell maturation through nitric oxide signaling17.
Our previous work has demonstrated that SASH1 regulates apoptotic pathways and is cleaved by Caspase-3 during UVC-induced apoptosis18. Beyond its roles in tumorigenesis, SASH1 has also been demonstrated to be involved in the regulation of melanogenesis by a novel p53/POMC/α‐MSH/Gαs/SASH1 cascade. Highlighting this, mutations in SASH1 resulting in hyperpigmentation19,20,21.
Our previous data have shown that chloropyramine, a known competitive reversible H1-receptor antagonist (also known as an H1 inverse agonist), can increase SASH1 protein levels in breast cancer cells22. Chloropyramine exerts its pharmacological action by competing with histamine for the H1 subtype histamine receptor. Chloropyramine has also been shown to inhibit VEGFR-3 and FAK, showing anti-cancer activity in several tumor types, with a decrease in cell proliferation23,24.
The backbone of first-line treatment for most lung cancer patients, without identified mutations in genes such as EGFR, comprises combinational therapies using cytotoxic chemotherapeutic agents such as cisplatin25, which cause an overwhelming level of irreparable DNA damage. These are selectively cytotoxic to rapidly dividing cells directing them towards apoptotic cell death26. Despite a typical initial efficacy of these agents, NSCLC tumors eventually develop resistance. The resensitisation of these cancer cells to chemotherapeutics is key to improving patient survival. Here, we show that increasing SASH1 levels via exogenous overexpression or using a compound, could be a new strategy to treat NSCLC.
SASH1 is an independent prognostic factor in NSCLC
To determine whether SASH1 was a prognostic factor for NSCLC, SASH1 mRNA expression was assessed between normal and tumor tissue in a NSCLC cohort (Fig. 1A), and between stages of disease (Fig. 1B). SASH1 mRNA expression was evaluated separately in adenocarcinoma and squamous cell carcinoma cohorts. All subtypes examined showed decreased SASH1 expression in the tumour tissue compared to normal tissue (Fig. 1C,D). Kaplan–Meier survival analysis was performed for all 1145 patients stratified using medium SASH1 expression as the cut-off. Evaluation of all NSCLC cases in the cohort indicated there was a significant difference in survival based on SASH1 expression, with high SASH1 showing improved survival (Fig. 1E; HR (95% CI): 1.74 (1.49–2.06), p = 6.3 × 10–11 for low SASH1 versus high SASH1, log-rank p < 0.0001)). However, separate analysis of adenocarcinoma and squamous cell cohorts showed that this stratification was only statistically significant in the adenocarcinoma subset. SASH1 expression in squamous cell carcinomas did not stratify patients survival (Fig. 1F). In contrast, overall survival for patients with SASH1 high expressing adenocarcinomas was associated with improved outcomes (Fig. 1G; HR (95% CI): 2.03 (1.47–2.8), p = 2.0 × 10–5 for low SASH1 versus high SASH1, log-rank p < 0.0001). Further protein bioinformatic analysis from The Protein Atlas database demonstrated that low SASH1 protein expression is evident in the majority of cases, with 10/11 cases having weak or negative intensity (Fig. 1H,I). The correlation of SASH1 mRNA and protein was determined to have an R2 value of 0.7115 within a lung cancer cohort (Fig. 1J).
To assess if low SASH1 expression independently predicts poor patient survival, we performed multivariable survival analyses, which included stage, gender and smoking history as co-variates. Consistent with above univariate analyses, in multivariate Cox proportional hazard analyses, low SASH1 expression significantly predicts poor survival outcome for patients with NSCLC (p = 0.0092) and lung adenocarcinoma (p = 0.0095) but not for squamous cell carcinoma (p = 0.2815) (Table 1). Thus, this indicates that SASH1 is an independent prognostic factor for lung adenocarcinoma.
Depletion of SASH1 increases the proliferation of NSCLC cells and confers cisplatin resistance
To determine whether SASH1 acts as a tumor suppressor in NSCLC, we next examined whether SASH1 depletion altered the proliferation of a panel of NSCLC cell lines. SASH1 depletion in the A549, H460 and H1299 NSCLC cell lines significantly increased cellular proliferation. An increase was also observed in HCC827 and H226 cancer cell lines but did not reach statistical significance (Fig. 2). No effect on cellular proliferation was observed in the non-tumorigenic HBEC cell lines (Fig. 2). This is consistent with other studies that have shown that depletion of SASH1 results in increased cellular proliferation in breast, lung, colon and ovarian cell lines2,3,6,10,17,22.
As platinum-based chemotherapy is among the most utilised chemotherapeutic treatment strategies in lung cancer, we examined the impact of SASH1 depletion on the cellular sensitivity of NSCLC cell lines to cisplatin. As shown in Fig. 3A–F, the depletion of SASH1 led to increased cell survival suggesting that SASH1 may mediate cisplatin resistance. SASH1 depletion in HBEC cells did not affect sensitivity to cisplatin, indicating this effect may be specifc to tumour cells. Exogenous overexpression of SASH1 has been shown to increase cell death in several tumor cell lines3,5,6,7. To investigate this in NSCLC cell lines, Flag-SASH1 protein was transiently over-expressed (Fig. 3M). It was observed that overexpression of SASH1 in the NSCLC cell lines resulted in a significant decrease in cell survival, when compared to cells expressing the Flag vector alone (Fig. 3G–L). Ectopic expression of SASH1 also yielded a decrease in cell survival of NSCLC cells treated with cisplatin. This suggests that increasing SASH1 protein levels in NSCLC may be a strategy to reduced tumour cell proliferation.
Chloropyramine treatment increases SASH1 protein expression and enhances NSCLC cell sensitivity to cisplatin
Previously, we hypothesised that pharmacologically increasing SASH1 levels may be a novel approach to cancer therapy. To identify compounds that increased SASH1 protein levels we performed connectivity mapping using the CMap database (Broad Institute27). This identified a direct correlation between chloropyramine treatment and SASH1 mRNA expression (p = 0.000005, z-score 2.431). Our earlier work in breast cancer indicated that chloropyramine can induce cell death via a SASH1-dependent mechanism22.
Here, we assessed the use of chloropyramine as a chemical agent to increase SASH1 protein levels and induce tumour cell killing of lung cancer cells. Treatment of NSCLC cells with chloropyramine increased SASH1 protein expression (Fig. 4A) and a significant decrease in cell survival at 25 μM for the HCC827, H-226 and H1299 cell lines and at 50 μM for all other NSCLC cell lines, with the exception of A549 cells (Fig. 4B–G). Interestingly, HBEC4 cells showed only a minor decrease in cell number at the higher dose threshold. The cells treated with chloropyramine were confirmed to be undergoing apoptosis via Annexin V and PI staining (Fig. 4H–K). The effect of cisplatin combined with chloropyramine was next examined in the HBEC and NSCLC cell lines. As shown in Fig. 4L–Q, the combination treatment with cisplatin and chloropyramine enhanced the induction of cell death in all NSCLC cell lines, compared with the cell death induced by either drug alone with the exception of the A549 and HBEC cells. Taken together, these data suggest that chloropyramine is effective at inducing cell death in lung cancer cells.
To determine whether the chloropyramine-induced cell death was SASH1-dependent, NSCLC cells were depleted of SASH1 using a targeted siRNA prior to treatment with chloropyramine (Fig. 4R–W). This demonstrated that SASH1 depletion partially rescued the cell death response in these cell lines, suggesting chloropyramine-induced cell death is at least in part dependent upon the function of SASH1.
SASH1 has been proposed as a tumor suppressor, based on the correlation of the presence of SASH1 mRNA expression with beneficial prognosis in several human cancers2,3,4,5,6,7,8,28,29,30,31 and the observation that loss or depletion of SASH1 enhances tumor cell line survival and invasiveness in vitro3,5,6,7,8. Our investigation of SASH1 mRNA expression in tumors has supported this data. However, in contrast to what we have observed here, our recently published work in breast cancer showed a strong association between high nuclear SASH1 protein expression and favorable outcome in ER + cases, suggesting that the prognostic impact may be context dependent22.
Here, we observed that overexpression of SASH1 at the protein level through exogenous gene transfection induced cell death. In contrast, downregulation of SASH1 using siRNA increased cellular proliferation, consistent with other SASH1 studies in malignant disease. We have previously described that the impact of SASH1 expression on proliferation of breast cancer cell lines occurs irrespective of the histological subtype22. Furthermore, similar observations have been made for one previous study in lung cancer and in a range of solid tumors including cervical, hepatocellular and thyroid carcinomas and osteosarcoma3,9,10,11,12,15. Although only a moderate difference in SASH1 protein expression was observed between the non-cancerous cell line HBEC4 and the lung cancer cell lines in our study, 5/11 lung cancer cases from the Human Protein Atlas database have non-detectable SASH1 protein levels. This supports the notion that SASH1 protein expression is regularly lost in lung tumours (Fig. 1H,I). As a novel observation we identified that low SASH1 expression is associated with resistance to cisplatin, whilst high SASH1 expression induces sensitivity to the chemotherapeutic agent.
One question that arises is whether or not SASH1 protein levels can be induced pharmacologically. Using connectivity mapping we previously identified chloropyramine as a potential inducer of SASH1 expression22. In our previous study, we identified that this agent induces cell death in a SASH1 dependent manner, increasing protein levels within the cells. In the present study we have made similar observations, suggesting that increasing SASH1 levels may also be a viable therapeutic strategy in NSCLC. The repurposing old agents as cancer therapeutics is gaining pace, as our understanding of the mode of action of these agents increases. The potential introduction of chloropyramine into cancer treatment regimens still requires extensive investigation. Chloropyramine is currently approved in some European countries as an anti-histamine agent and has the advantage of minimal side effects. The further investigation of the mechanism by which chloropyramine increases SASH1 level will allow the development of new-targeted agents to increase the efficacy of targeting SASH1 as a cancer therapy.
Although changes to SASH1 expression have been linked with several other diseases, these associations need further investigation to cement the role of SASH1 as a tumor suppressor relevant to cancer prognoses, particularly within the context of apoptosis, cell cycle and proliferation. In support of this, our study has demonstrated that SASH1 does function within the cancer phenotype, with a prominent role in apoptosis. Agents that upregulate SASH1 are potential novel approaches to the management of lung cancer and warrant further preclinical and clinical studies of chloropyramine.
Cell culture and transfection
Cell lines were cultured at 37°C with 5% CO2 in media as outlined in Table 2. Chloropyramine (Sigma-Aldrich) was added to adherent cultured cells 24 h after seeding at the indicated concentrations (0–100 μM). Cancer cell lines include Adenocarcinoma (A549, H1299 and HCC827), Large cell carcinoma (H460) and Squamous cell carcinoma (H-226). All cell lines were originally sourced from American Type Culture Collection (ATCC).
siRNA experiments where performed as previously described19, briefly esiRNAs (Sigma) targeting SASH1 or non-specific control oligos (20 nM) were transfected using RNAiMax (Invitrogen) as per the manufacturer's instructions. Double-transfections were performed 24 h apart and samples were analysed 72 h post the initial transfection, where optimal SASH1 depletion was observed. For overexpression studies, the full-length SASH1 cDNA was cloned into the mammalian expression vector pCMV6 (Origene). 3 μg of DNA (SASH1-Flag or Flag) and 8 μL of Fugene HD were used to transfect cells in a T25 flask, as per the manufacturer's instructions. Cells were assayed 48 h post-transfection for optimal overexpression and death assessment.
Immunoblotting was carried out as described previously32. Uncropped blots are provided in the supplementary data file.
Cell death assay
Following incubation of cells with the indicated treatments, propidium iodide (10 μg/ml) and Hoechst (1 μg/ml) were added 30 min before imaging. Cells were imaged on an IN Cell Analyzer 2200 (GE Healthcare; 10 × objective). Live/dead cell analysis was performed using IN Cell analysis software.
Apoptosis was assessed using Annexin PI staining as per Promega Annexin V-FITC apoptosis detection kit instructions.
Cell proliferation assay
Control or SASH1 depleted lung cancer cells were seeded at 2500 cells per well in 96 well plates (Nunc). Cells adhered and then imaged every 2 h for 96 h in an IncuCyte ZOOM live cell imager (Essen Bioscience) to calculate confluence.
Drug screen with connectivity mapping
An established gene expression connectivity mapping approach33,34 was employed to screen candidate drugs for their potential to induce SASH1 expression. Chloropyramine was identified as an agent associated with upregulation of SASH1 expression as previously described in breast cancer22.
Figure 1A–D were generated using The Cancer Genome Atlas (TCGA) lung cancer RNAseq and clinical datasets35,36. For this, levels 3, log2-transformed mRNA expression levels and associated clinical files were downloaded from the NIH-NCI Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov) for both adjacent normal (henceforth "normal") and lung tumor samples. Samples from the lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were considered separately, as well as combined. The latter comprised the non-small cell lung cancer (NSCLC) dataset. Statistical analyses and generation of plots were performed in the R statistical environment (version 3.6, R Core Team, Vienna, Austria). The p values were calculated using the (unpaired) Mann–Whitney U test, all relative to normal tissue. They have not been adjusted to account for multiple hypothesis testing. Kaplan–Meier survival curves (Fig. 1E–G) were generated from Kaplan–Meier plotter using medium expression cutoff with multivariate analysis performed. Survival analyses were performed using the SASH1 microarray probe 226022_at. Statistical analyses of survival curves included log-rank tests, with p values reported, as well as univariate and multivariate Cox proportional hazard analyses, with hazard ratios (HR) and 95% confidence intervals (CI) reported. In addition, for the SASH1low and SASH1high groups, survival proportions at 50-month intervals and median survival in months were reported. SASH1 mRNA and protein levels were compared in 77 lung cancer cell lines. Normalized log2-transformed RSEM mRNA levels, in transcripts per million (TPM), were obtained from reference31. Protein levels were determined by mass spectrometry and represent normalized quantities obtained from reference37. Linear regression and Spearman correlation analyses were used to determine the mRNA-protein correlation in the cell lines. SASH1 protein expression was investigated in a tumor cohort utilising data from The Human Protein Atlas. Data from the SASH1 Antibody HPA029947 was used for the data presented38,39.
Cell proliferation analysis was carried by Graph Pad Prism, with T Test used to assess differences between subsets. Biological replicates performed as indicated with P values where assigned *P < 0.05, **P < 0.005 and ***P < 0.0005.
Burgess, J. T. et al. DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer Manag. 3, 159–173 (2014).
Zeller, C. et al. SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene 22, 2972–2983 (2003).
Chen, E., Chen, Y., Dong, L. & Zhang, J. Effects of SASH1 on lung cancer cell proliferation, apoptosis, and invasion in vitro. Tumour Biol. 33, 1393–1401 (2012).
Bailey-Wilson, J. E. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. J. Hum. Genet. 75, 460–474 (2004).
Sato, M., Shames, D. S., Gazdar, A. F. & Minna, J. D. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2, 327–343 (2007).
Rimkus, C. et al. Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br. J. Cancer. 95, 1419–1423 (2006).
Yang, L. et al. Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells. Tumour Biol. 33, 2255–2263 (2012).
Meng, Q. et al. SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol. Cell. Biochem. 373, 201–210 (2013).
Lin, S. et al. Effects of SASH1 on melanoma cell proliferation and apoptosis in vitro. Mol. Med. Rep. 6, 1243–1248 (2012).
Sun, D. et al. SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol. 8, 12276–12283 (2015).
He, P., Zhang, H.-X., Sun, C.-Y., Chen, C.-Y. & Jiang, H.-Q. Overexpression of SASH1 inhibits the proliferation, invasion, and EMT in hepatocarcinoma cells. Oncol. Res. 24, 25–32 (2016).
Chen, H., Wang, D. & Liu, Y. SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway. Mol. Med. Rep. 4, 3613–3618 (2016).
Lin, S. et al. Promoter methylation assay of SASH1 gene in breast cancer. JBUON. 18, 891–898 (2013).
Peng, L., Wei, H. & Liren, L. Promoter methylation assay of SASH1 gene in hepatocellular carcinoma. JBUON 19, 1041–1047 (2014).
Koch, C. A., Anderson, D., Moran, M. F., Ellis, C. & Pawson, T. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins. Science 252, 668–674 (1991).
Claudio, J. O. et al. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene 20, 5373–5377 (2001).
Coulombe, P. et al. Endothelial Sash1 is required for lung maturation through nitric oxide signaling. Cell Rep. 27, 1769–1780 (2019).
Burgess, J. T. et al. Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death Dis. 7, e2469 (2016).
Zhou, D. et al. p53 regulates ERK1/2/CREB cascade via a novel SASH1/MAP2K2 crosstalk to induce hyperpigmentation. J. Cell. Mol. Med. 21, 2465–2480 (2017).
Courcet, J. B. et al. Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma. Eur. J. Hum. Genet. 23, 957–962 (2015).
Zhou, D. et al. A novel P53/POMC/Gas/SASH1 autoregulatory feedback loop and pathologic hyperpigmentation. Mol. Med. 21, 2 (2019).
Burgess, J. T. et al. SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. Oncotarget. 7, 72807–72818 (2016).
Kurenova, E. et al. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle 13, 2542–2553 (2014).
Kurenova, E. V. et al. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J. Med. Chem. 15, 4716–4724 (2009).
Casaluce, F. et al. The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. Clin. Investig. (Lond) 4, 369–383 (2013).
Ahmad, S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers. 7, 543–566 (2010).
Lamb, J. et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
Zhou, D. et al. SASH1 regulates melanocyte transepithelial migration through a novel Gαs-SASH1-IQGAP1-E-Cadherin dependent pathway. Cell. Signal. 25, 1526–1538 (2013).
Yang, L. et al. Clinical significance of SASH1 expression in glioma. Dis. Markers. 20, 1–7 (2015).
Martini, M., Gnann, A., Scheikl, D., Holzmann, B. & Janssen, K. P. The candidate tumor suppressor SASH1 interacts with the actin cytoskeleton and stimulates cell-matrix adhesion. Int. J. Biochem. Cell Biol. 43, 1630–1640 (2011).
Ghandi, M. et al. Next-generation characterization of the cancer cell line encyclopedia. Nature 569, 503–508 (2019).
Bolderson, E. et al. Human single-stranded DNA binding protein 1 (hSSB1/NABP2) is required for the stability and repair of stalled replication forks. Nucleic Acids Res. 42, 6326–6336 (2014).
Zhang, S. D. A simple and robust method for connecting small-molecule drugs using gene-expression signatures. BMC Bioinform. 9, 258 (2008).
Zhang, S. D. & Gant, T. W. sscMap: An extensible Java application for connecting small-molecule drugs using gene-expression signatures. BMC Bioinform. 10, 236 (2009).
Collisson, E. A. et al. Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network. Nature 511, 543–550 (2014).
Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
Nusinow, D. P. et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell 180, 387–402 (2020).
Uhlén, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteom. 4, 1920–1932 (2005).
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
This work was supported by a Grant from the Princess Alexandra Hospital Research Foundation, National Breast Cancer Foundation and a Queensland Senior Clinical Research Fellowship. JB is supported by an Advance Queensland Early-career Research Fellowship. EB is supported by an Advance Queensland Senior Research Fellowship. MNA is supported by a NHMRC Early Career Biomedical Fellowship (1091589) and is an IASLC Foundation Awardee supported by the International Association for the Study of Lung Cancer Foundation.
K.J.O. and D.J.R. are founders of CARP Pharmaceuticals. E.B, D.J.R and K.J.O. are founders of Carpe Vitae Pharmaceuticals. E.B., J.T.B, K.J.O., D.J.R. are inventors on patent applications filed by Queensland University of Technology. All other authors have no known competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Burgess, J.T., Bolderson, E., Adams, M.N. et al. SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. Sci Rep 10, 18605 (2020). https://doi.org/10.1038/s41598-020-75625-1
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.